Kaiser Permanente Oyster Point Cancer Center

NGM Bio, located in South San Francisco, CA, is at the forefront of life-changing science, dedicated to discovering and delivering innovative medicines for individuals affected by various diseases. The company is currently advancing its EMERALD Phase 2 Clinical Trial of NGM120, aimed at addressing Hyperemesis Gravidarum, also known as extreme pregnancy sickness. With a robust and diverse pipeline of biologic drug candidates developed in-house, NGM Bio focuses on tackling significant unmet medical needs that impact millions globally. The organization is also exploring partnership opportunities across its comprehensive product candidate and research portfolio. Generated from the website